Recruiting
Study on Azathioprine for Preventing Relapse in Patients with Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOG-AD) After First Attack
Registered drug
Study on Azathioprine for Preventing Relapse in Patients with Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOG-AD) After First Attack
Registered drug
- Disease:Anti-myelin-associated glycoprotein antibodies positive
- Substances:AzathioprineHydrocortisone+1
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Azathioprine
- Sponsor:Hospices Civils De Lyon